Skip to main content
finq
OS
Search ticker, company, or fund...
⌘
K
Capture
Closed
TSHA: Taysha Gene Therapies, Inc. Stock Analysis | finqOS
Healthcare · Biotechnology
The Story
TSHA
The Story
TSHA
Loading chart data...
Current State
Balance holding
The verdict
Good business
Weak
Revenue growth
-46.1% / yr
Operating margin
-1774.4%
ROIC
-47.3%
Financially safe
Stretched
Debt / equity
0.08×
Interest coverage
-2501.2×
Current ratio
14.04×
Taysha Gene Therapies, Inc.
TSHA
NASDAQ Global Select
·
USD
·
Closed
Story
Data
Canvas
Capture
Save
Taysha Gene Therapies, Inc.
TSHA
NASDAQ
·
USD
·
Closed
$5.86
−0.26%
$5.86
−$0.01 (0.26%)
52W Range
70th
pctl
Volume
0.66×
avg
Mkt Cap
1.87B
USD
P/E
-15.3
TTM
Div Yield
–
ann
52W Range
70th
pctl
Volume
0.66×
avg
Market Cap
1.87B
USD
P/E Ratio
-15.3
TTM
Div Yield
-
ann
Overview
Financials
Peers
Sentiment
Analysis
Transcripts
Holders
Company
SEC Filings
Overview
Financials
Peers
Sentiment
Analysis
Transcripts
Holders
Company
SEC Filings